Results 221 to 230 of about 8,133 (247)

Cardiovascular Efficacy of GLP‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8407-8417, September 2026.
ABSTRACT Aims To evaluate the cardiovascular efficacy and absolute benefit of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) by baseline estimated glomerular filtration rate (eGFR). Materials and Methods PubMed and EMBASE were searched to 29 April 2026 for randomized placebo‐controlled trials of GLP‐1RAs in adults with type 2 diabetes or ...
Masashi Hasebe, Chen‐Yang Su, Daisuke Yabe, Satoshi Yoshiji   +3 more
wiley   +1 more source

Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes. [PDF]

Diabetol Int
Saito R, Harada N.
europepmc   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7768-7778, September 2026.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Decoding incretin resistance: a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy. [PDF]

Amino Acids
Fajkić A, Lam YW, Belančić A.
europepmc   +1 more source

JNK3 regulates β cell responses to incretins in human islets and mouse models. [PDF]

J Clin Invest
Louzada RA, Gonzalez Medina M, Pita-Grisanti V, Bouviere J, Neves AF, Almaça J, Han MS, Davis RJ, Leibowitz G, Blandino-Rosano M, Bernal-Mizrachi E.   +10 more
europepmc   +1 more source

Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8709-8713, September 2026.
Michelantonio De Fano, Rachele Tortoriello, Stefania Rucco, Sofia Corio, Marcello Manco, Edoardo Guerrini, Francesca Porcellati   +6 more
wiley   +1 more source

Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia for Dentistry. [PDF]

Anesth Prog
McKenzie C, DeBernardo A, Schwartz P.
europepmc   +1 more source

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis. [PDF]

J Clin Transl Endocrinol
Lei WS, Chen X, Zhao L, Daley T, Phillips B, Rickels MR, Kelly A, Kindler JM.   +7 more
europepmc   +1 more source

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Efficacy and Adverse Events. [PDF]

Arch Clin Med Case Rep
Radparvar I, Agrawal DK.
europepmc   +1 more source

Incretins in the Therapy of Diabetic Kidney Disease [PDF]

International Journal of Molecular Sciences, 2021
Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality.
Andrzej Pawlik, Weronika Bielka
exaly   +2 more sources